Lack of Association Between GSTM1, GSTP1, and GSTT1 Gene Polymorphisms and Asthma in Adult Patients From Rome, Central Italy

S Piacentini,1 R Polimanti,1,2 B Moscatelli,2 MA RE,2 D Manfellotto,2 M Fuciarelli1

1Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
2Clinical Pathophysiology Center, AFaR, “San Giovanni Calibita” Fatebenefratelli Hospital, Isola Tiberina Rome, Italy

Abstract

Background: Asthma is a complex multifactorial disease that is not yet fully understood. Oxidative stress due to an imbalance between the oxidative forces and the antioxidant defense systems has been implicated in asthma pathogenesis. However, much debate still surrounds the key genetic factors involved in the development of this disease. Candidate genes include the glutathione S-transferases (GSTs). In particular, mu, pi, and theta classes of GSTs play an important role in regulating inflammatory responses. However, few and contradictory data are available on the association between asthma development and GST gene polymorphisms (GSTM1, GSTP1, and GSTT1).

Objective: To investigate whether GSTM1, GSTT1, and GSTP1 polymorphisms are associated with asthma development.

Methods: We recruited 200 unrelated healthy individuals and 199 asthmatic patients from Rome in Central Italy. Genotyping of GSTM1 and GSTT1 genes was performed by a multiplex polymerase chain reaction (PCR) while the GSTP1 polymorphism (rs1695) was determined using PCR-restriction fragment length polymorphism analysis.

Results: Our results suggest that the GST polymorphisms analyzed are not associated with asthma, confirming the uncertain role of GST genes in the development of asthma.

Conclusions: Oxidative stress is certainly involved in the development of asthma, and GSTs may therefore influence asthma risk, although, as our results show, their role in pathogenesis remains to be elucidated. Future studies should focus on the interactions of GST genes with the environment and other antioxidant genes to shed light on the role of GSTs in asthma.

Introduction

Asthma is a disorder of the airways characterized by several symptoms such as airflow obstruction, airway inflammation, and hyperresponsiveness. These symptoms, however, can in some cases resolve, either spontaneously or as a result of treatment [1]. A clinical diagnosis is made on the basis of several criteria such as physical findings, medical history, and exclusion of diagnoses that mimic asthma [2]. The study of genetic factors involved in complex pathologies such as asthma is arduous, not only because of human genetic variability, or incomplete penetrance, but also because, in complex disease studies, the importance and strength of gene to gene and gene to environment interactions need to be considered [3]. The gene to environment interaction is a mechanism where genes define the potential and limitations of an organism’s reaction to environmental conditions. The effects of genetic and environmental components overlap, and in several cases may be dependent on each other. Thus, a certain phenotype or disease may be caused by a genetic factor, by an environmental condition, or by a combination of the two.

Several studies have highlighted that oxidative stress damages pulmonary function and might act as a key player in the worsening of asthma symptoms [4]. The damage caused by oxidative injury leads to an increase in airway reactivity and/or secretions, and also influences the production of chemoattractants and increases vascular permeability. All these factors exacerbate inflammation, which is a hallmark of asthma. Several candidate genes have been implicated in the development of atopy and asthma. In particular, those involved in oxidative stress responses are candidates for asthma. The prevalence of candidate gene polymorphisms varies considerably worldwide, and accordingly, ethnicity should be considered as a factor that might act on and influence asthma development. Furthermore, previous data based on intra- and inter-population frequency differences suggest that the association between a given genetic polymorphism and asthma cannot be extrapolated from one ethnic group to another [5]. Phase II detoxification enzymes, particularly classes of glutathione S-transferases (GSTs), play an important role in inflammatory responses triggered by xenobiotic or reactive oxygen compounds [6]. GSTs are characterized by a different localization in cells and are known to belong to the cytosolic, the mitochondrial, or the membrane-bound microsomal families. Alpha, Mu, Omega, Pi, Sigma, Theta and Zeta classes characterize the cytosolic family [7]. GST genes are polymorphic and research by several groups in recent years has focused on evaluating the association between certain allelic variants and several complex diseases and explaining their role. The inability of GST variant enzymes to detoxify reactive oxygen species (ROS) contributes to the activation of the inflammatory process, bronchoconstriction, and the exacerbation of asthma symptoms. An increasing risk for asthmatic disease development and an increase in individual susceptibility to the pro-allergic effects of xenobiotics have been demonstrated to be linked to functional polymorphisms of GST enzymes [6]. In particular, GSTM1 and GSTT1 null polymorphisms and a single nucleotide polymorphism (SNP) of GSTP1 (rs1695; Ile105Val) may influence the pathogenesis of respiratory diseases. Numerous studies have documented associations between genes implicated in the oxidative stress response and respiratory phenotypes, but the data suggest that they may not be consistent across ethnic groups owing to differences in intra- and inter-ethnic allele frequencies [8]. To date, few studies on the association between these genes and the risk of asthma and related phenotypes have been conducted in the Italian population [9,10]. Due to the paucity of data in this field, we undertook a descriptive study to evaluate the association between GSTM1, GSTT1, and GSTP1 polymorphisms and asthma in a sample of individuals from Rome, Italy.

Materials and Methods

The participants were recruited in Rome, Central Italy. The sample consisted of 199 patients with asthma (mean age [SD], 50.9 [1.4] years) and 200 healthy controls (mean age, [SD] 53.9 [1.2] years) living in the same geographical area. Both patients and controls were recruited from the clinical pathophysiology center of “San Giovanni Calibita” Fatebenefratelli Hospital of Rome during a routine health care visit. Asthma diagnosis was based on the following criteria: (1) a current diagnosis by a physician, (2) symptoms, and (3) use of anti-asthma medication according to the Global Initiative on Asthma criteria [11]. None of the controls had a history of pulmonary disease or atopy. Information on demographic characteristics, medical history, smoking habits, and occupational risk were obtained in face-to-face interviews with medical staff using a structured questionnaire. All the interviews were conducted in accordance with Italian law, which guarantees individual privacy. We distinguished between active smoking (smoker, ex-smoker, and nonsmoker) and passive smoking (exposed, not exposed). For risk at work we considered occupational exposure to chemical substances, irritating material, or toxic dust. Buccal cells were collected with an oral swab from each participant. The samples were stored at room temperature until they were returned to the laboratory, where they were stored at 4°C before processing. Written informed consent was obtained from all individuals and the study was approved by the hospital’s ethics committee.

DNA from buccal cells was obtained using the phenol: chloroform: isoamyl alcohol method [12]. Genotyping of GSTM1 and GSTT1 was performed by a multiplex polymerase chain reaction (PCR) reaction [13]. The PCR products were analyzed on 1.5% agarose gels stained with ethidium bromide (10 mg/mL). A fragment of 273 base pairs (bp) indicated the presence of GSTM1, a fragment of 480 bp indicated the presence of GSTT1, and a fragment of 312 bp indicated the positive internal control, CYP4501A1. This technique makes it possible to discriminate a null phenotype (gene deletion in homozygous status) from a positive phenotype (wild genotype in homozygous and heterozygous status). The GSTP1 Ile105Val polymorphism was analyzed by PCR-restriction fragment length polymorphism analysis [14]. The PCR products were digested for 24 hours at 37°C in 20 μL of 2 U BsmAI (New England Biolab). The digestion products for GSTP1*Ile105Val revealed the presence of 3 different patterns: the A/A wild-type homozygote (Ile/Ile) showed a 176-bp fragment;
the G/G polymorphic homozygote (Val/Val) showed the expected 91- and 85-bp fragments; and the A/G heterozygote (Ile/Val) showed 176-, 91-, and 85-bp fragments. To ensure the reliability of the results, approximately 15% of the samples were randomly selected and genotyped independently by a second researcher using the same protocol. In all cases the results coincided.

**Statistical Analysis**

All data analyses were carried out using the statistical software SPSS 15.0. Descriptive analyses were performed using t tests for continuous variables (age and body mass index [BMI]), whereas the χ² and Fisher exact tests were used for categorical variables (sex, smoking habits, and genotype distribution). The results of genotyping procedures were used to verify the Hardy–Weinberg equilibrium. Significance levels for 2-sided tests of the main effects were set at α=0.05. Logistic regression was used to calculate adjusted odds ratios (ORs) and 95% CIs for the association between GST gene polymorphisms and asthma.

**Results**

We analyzed 199 unrelated asthmatic adults, approximately 74% of whom were atopic, and 200 unrelated healthy controls. Table 1 summarizes the characteristics of both groups. No significant differences were found between asthmatic patients and healthy controls for age distribution, sex ratio, or any of the other characteristics analyzed.

Data regarding the genotype frequencies of the GSTP1 Ile105Val polymorphism and the GSTM1 and GSTT1 homozygous deletions are shown in Table 2. GSTP1 genotype frequencies were in Hardy–Weinberg equilibrium. The genotype frequencies of GST polymorphisms in our study population were within the ranges reported previously in Italy and in other European populations [15].

No significant differences in the genotype distributions of the GSTM1, GSTP1 or GSTT1 genes were found between asthmatics and healthy controls. X² tests and adjusted ORs did not show any associations between genetic polymorphisms and asthma.

**Table 1. Characteristics of the Study Population**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Asthmatics</th>
<th>Controls</th>
<th>Statistical Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age, y</td>
<td>52.4 (1.2)</td>
<td>54.9 (1.0)</td>
<td>t=1.60 P=.110</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>82 (41)</td>
<td>89 (44)</td>
<td>χ²=0.32 P=.57</td>
</tr>
<tr>
<td>Female (%)</td>
<td>117 (59)</td>
<td>111 (56)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD) BMI, kg/m²</td>
<td>25.3 (0.3)</td>
<td>25.0 (0.2)</td>
<td>t=0.83 P=.405</td>
</tr>
<tr>
<td>Atopy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atopic</td>
<td>148 (74)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Nonatopic</td>
<td>51 (26)</td>
<td>200 (100)</td>
<td></td>
</tr>
<tr>
<td>Active smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>41 (21)</td>
<td>41 (21)</td>
<td>χ²=6.65 p=0.036*</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>42 (21)</td>
<td>64 (32)</td>
<td></td>
</tr>
<tr>
<td>Nonsmoker</td>
<td>116 (58)</td>
<td>95 (47)</td>
<td></td>
</tr>
<tr>
<td>Passive smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed</td>
<td>78 (39)</td>
<td>61 (31)</td>
<td>χ²=2.95 p=0.085</td>
</tr>
<tr>
<td>Occupational risk</td>
<td>62 (33)</td>
<td>48 (24)</td>
<td>χ²=2.12 p=0.137</td>
</tr>
</tbody>
</table>

**Table 2. Genotype Distribution and Odds Ratios (ORs) for Asthmatics and Controls**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Genotype</th>
<th>Asthmatics</th>
<th>Controls</th>
<th>P Value</th>
<th>Crude OR (95% CI)</th>
<th>Adjusted OR (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSTM1</td>
<td>Null</td>
<td>109 (55)</td>
<td>101 (51)</td>
<td>.451</td>
<td>1.19 (0.80-1.76)</td>
<td>0.95 (0.65-1.40)</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>90 (45)</td>
<td>99 (49)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTP1*I105V (rs1695)</td>
<td>I105/I105</td>
<td>82 (41)</td>
<td>96 (48)</td>
<td>.370</td>
<td>1.32 (0.88-1.96)</td>
<td>1.21 (0.54-2.70)*</td>
</tr>
<tr>
<td></td>
<td>I105/V105</td>
<td>99 (50)</td>
<td>87 (43)</td>
<td></td>
<td>1.07 (0.53-2.14)</td>
<td>0.82 (0.37-1.84)*</td>
</tr>
<tr>
<td></td>
<td>V105/V105</td>
<td>18 (9)</td>
<td>17 (9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTT1</td>
<td>Null</td>
<td>72 (36)</td>
<td>59 (30)</td>
<td>.189</td>
<td>1.36 (0.89-2.06)</td>
<td>1.08 (0.59-1.55)</td>
</tr>
<tr>
<td></td>
<td>Positive</td>
<td>127 (64)</td>
<td>141 (70)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Data are expressed as no. (%) of patients unless otherwise indicated.

Abbreviations: BMI, body mass index.

*Data are expressed as no. (%) of patients unless otherwise indicated.

*Odds ratios and 95% CIs adjusted for age, sex, body mass index, active smoking, passive smoking, and occupational risk.

Dominant genetic model (wt/mut + mut/mut vs wt/wt);

Recessive genetic model (mut/mut vs wt/mut + wt/wt).
Discussion

The GST superfamily of enzymes is involved in xenobiotic biotransformation and in protection against ROS, using a wide range of oxidative stress metabolites as substrates [5]. Inflammation is a key component of asthma, and previous studies have reported that oxidative stress is implicated in inflammation processes [4]. Furthermore, a defect in ROS detoxification processes may influence the development of asthma or the worsening of symptoms [4]. Several studies have previously demonstrated a significant association between individuals with reduced or no GSTM1, GSTP1, or GSTT1 activity and the risk of developing lung disease [16,17], but a recent meta-analysis has shown the extreme heterogeneity of associations between the GST genotype and asthma risk [18]. The results of our work suggest the absence of an association between GSTM1, GSTT1, GSTP1 and asthma in adults and do not sustain the hypothesis that these genotypes are involved in increasing risk. The lack of association could be due to other interactions between host factors (not only gene polymorphisms) and the environment.

Respiratory diseases, such as asthma and its intermediate phenotypes, are the result of interactions between multiple genetic and environmental factors. The existence of a link between certain GST allelic variants and asthma remains to be demonstrated and clarified. The potential involvement of GSTs in modulating oxidative stress, activating certain substrates, and producing lipid mediators of arachidonic acid may therefore exert a direct or indirect influence on asthma risk. Our results, however, confirm the uncertain role of GST genes in the development of asthma. Future studies with large samples should focus on interactions between GST genes and environmental oxidative exposure and other genes involved in antioxidant pathways in order to explain the role of GST gene polymorphisms in asthmatic phenotypes.

Acknowledgments

This research was supported by a grant from the University of Rome “Tor Vergata” (Ricerche di Ateneo, RSA 2009) assigned to M.F.

References

13. Abdel-Rahman SZ, El-Zein RA, Anwar WA, Au WW. A multiplex


Manuscript received January 3, 2011; accepted for publication February 14, 2012.

Maria Fuciarelli
Via della Ricerca Scientifica, 1
00133 Rome
Italy